All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Melanotan II and skin cancer: separating hype from actual risk

Alpha Club Supplements UK

TikTok creator

118.2K viewsWatch on TikTok→

Quick answer

Melanotan II activates melanocortin receptors (primarily MC1R and MC4R), stimulating melanin production and offering some theoretical photoprotection, but it also promotes melanocyte proliferation via pathways that overlap with those implicated in melanoma development. Case reports document both new nevi formation and existing mole changes following use, raising concerns that extend beyond detection difficulty alone. Melanotan II has no approved human indication in the US, EU, or UK, and the FDA has explicitly warned consumers against products containing it.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @alphaclubsupps actually say?

The creator's core argument is reasonable on the surface: MT2 doesn't directly cause skin cancer, it just "darkens moles and therefore they become far more difficult to detect changes in those moles." He frames the cancer concern as a detection problem, not a biological one. He also says MT1 and MT2 were "designed to protect you from skin cancer" by increasing melanin, which reduces burning and UV damage. Credit where it's due: he's trying to add nuance to a black-and-white narrative. But nuance done sloppily can be just as misleading as the fear-mongering he's criticizing.

He's also casually disclosing personal use: "I've been taking it for the last couple of months and fucking it's brilliant." That's not a clinical endorsement, but it frames the video as advocacy, which shapes how the science gets presented.

Does the science back this up?

Partly, but the creator significantly understates the actual risk picture. Melanotan II is a synthetic analog of alpha-melanocyte stimulating hormone (alpha-MSH). It does stimulate melanogenesis, and higher baseline melanin does correlate with reduced UV-induced DNA damage in fair-skinned individuals. That part is real. The original University of Arizona research in the 1980s and 1990s, led by Mac Hadley and Victor Hruby, was genuinely aimed at photoprotection.

But the mole-darkening issue is not just a detection problem. Multiple case reports document new melanocytic nevi appearing after melanotan use, and existing nevi changing in ways consistent with dysplasia, not just pigmentation shifts. A 2009 case series published in the Journal of the American Academy of Dermatology (Dawson et al.) documented mole changes requiring biopsy following melanotan use. A 2018 case report in Clinical and Experimental Dermatology (Hughes et al.) linked melanotan II use to a melanoma diagnosis in a 26-year-old. These are case reports, not randomized trials, but they describe biological changes, not just visual obscuration.

The deeper concern is that melanocortin receptor activation, specifically MC1R, plays a role in melanocyte proliferation pathways. Driving those pathways in a person with pre-existing atypical nevi isn't equivalent to just getting a tan.

What did they get wrong (or right)?

He got the basic biology directionally correct: melanin does provide some photoprotection, and the detection-difficulty argument is a real and documented concern. Dermatologists have flagged that mole mapping becomes less reliable after melanotan use, and that's a legitimate clinical issue worth raising.

Where he goes wrong is collapsing the entire risk picture into a single mechanism. Saying "it's not MT1 and MT2 directly give you skin cancer, it's just" detection difficulty is an oversimplification that lets the peptide off the hook too easily. The existing case literature suggests the relationship between MC1R agonism and melanocyte behavior is more complicated than "melanin good, no burn, no cancer."

He also compares the concern to fear-mongering around testosterone and GLP-1s, which is a rhetorical move, not an argument. Those are not equivalent risk profiles. Melanotan II has no approved human use in any major regulatory jurisdiction. The FDA, EMA, and MHRA have all issued warnings against it. That's worth mentioning when you're telling 118,000 people not to be put off by the risk narrative.

What should you actually know?

If you're considering melanotan II, the detection problem alone should give you pause. Regular skin checks are a primary tool for catching melanoma early, when it's most treatable. If a compound systematically changes the appearance of your moles, you've just made that tool less reliable, regardless of whether the peptide itself is carcinogenic.

The broader point is that "no direct causation proven" is not the same as "safe." Melanotan II has never completed Phase III clinical trials. The University of Arizona team shelved it partly due to side effect concerns including nausea, spontaneous erections, and cardiovascular effects. What's being sold online is unregulated, often dosed without standardization, and injected without medical supervision.

Anyone using this compound should be under the care of a dermatologist who knows about the use and is doing baseline mole mapping. That's not fear-mongering. That's just the minimum reasonable precaution when you're activating melanocyte pathways with a synthetic hormone analog that regulators in multiple countries have warned against.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Melanotan II and skin cancer: separating hype from actual risk, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Melanotan II and skin cancer: separating hype from actual risk should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

Use the health tools and supporting evidence to prepare questions for your clinician.

Claim verdict

The useful answer behind this video

Claim being checked

Melanotan II activates melanocortin receptors (primarily MC1R and MC4R), stimulating melanin production and offering some theoretical photoprotection, but it also promotes melanocyte proliferation via pathways that overlap with those implicated in melanoma development.

FormBlends verdict

Melanotan II activates melanocortin receptors (primarily MC1R and MC4R), stimulating melanin production and offering some theoretical photoprotection, but it also promotes melanocyte proliferation via pathways that overlap with those implicated in melanoma development. Case reports document both new nevi formation and existing mole changes following use, raising concerns that extend beyond detection difficulty alone. Melanotan II has no approved human indication in the US, EU, or UK, and the FDA has explicitly warned consumers against products containing it.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Melanotan II activates melanocortin receptors (primarily MC1R and MC4R), stimulating melanin production and offering some theoretical photoprotection, but it also promotes melanocyte proliferation via pathways that overlap with those implicated in melanoma development. Case reports document both new nevi formation and existing mole changes following use, raising concerns that extend beyond detection difficulty alone. Melanotan II has no approved human indication in the US, EU, or UK, and the FDA has explicitly warned consumers against products containing it.
  • Melanotan II has no approved human indication in the US, EU, or UK. The FDA, EMA, and MHRA have all issued warnings against consumer use of melanotan products.
  • The original photoprotection research at the University of Arizona is real, but neither MT1 nor MT2 advanced to approved therapeutic use, partly due to the side effect profile identified during development.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Melanotan II has no approved human indication in the US, EU, or UK. The FDA, EMA, and MHRA have all issued warnings against consumer use of melanotan products.
  • The original photoprotection research at the University of Arizona is real, but neither MT1 nor MT2 advanced to approved therapeutic use, partly due to the side effect profile identified during development.
  • At least one case report (Hughes et al., 2018, Clinical and Experimental Dermatology) documents a melanoma diagnosis in a 26-year-old following melanotan II use, alongside biological changes in existing nevi, not just cosmetic darkening.
  • Dawson et al. (2009, Journal of the American Academy of Dermatology) documented mole changes requiring biopsy in melanotan users, a finding that goes beyond the detection-difficulty framing offered in this video.
  • MC1R agonism, the mechanism behind melanotan's tanning effect, also drives melanocyte proliferation pathways that overlap with those studied in melanoma biology. The claim that the peptide is biologically inert with respect to cancer risk is not established.
  • Anyone using melanotan II should have baseline mole mapping performed by a dermatologist before use and disclose the use explicitly, because standard visual monitoring is less reliable after the compound changes mole pigmentation.
  • Unregulated injectable peptides purchased online carry contamination and dosing risks entirely separate from the pharmacological concerns discussed in this video.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Alpha Club Supplements UK · TikTok creator

118.2K views on this video

Replying to @Morph MT2 gives you skin cancer… or does it? 🤔 This is classic rage bait. There’s no solid evidence that MT2 directly causes skin cancer. In fact, it was originally developed to help protect the skin by increasing melanin ☀️ More melanin = Less burning 🔥 Less UV damage ⚠️ Less sun exposure needed to tan 🌴 So where does the “skin cancer” narrative come from? 👉 MT2 can darken existing moles 👉 That can make changes harder to spot early 👉 That’s where the perceived increased

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Alpha Club Supplements UK, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.